You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Marburg Virus Prophylactic Medical Countermeasure

    SBC: Flow Pharma, Inc.            Topic: CBD18A002

    Flow Pharma, Inc. is a biotechnology company in the San Francisco Bay Area developing fully synthetic cytotoxic T lymphocyte (CTL)stimulating peptide vaccines for Marburg virus. The FlowVax vaccine platform allows us to create dry powder formulations of biodegradablemicrospheres and TLR adjuvants incorporating class I and class II T cell epitopes. FlowVax vaccines can be designed for delivery by i ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  2. Brain Targeting Nanoparticle for Drug Delivery in Traumatic Brain Injury

    SBC: Weinberg Medical Physics, Inc.            Topic: DHA18A001

    There is an urgent need to bypass or cross the blood brain barrier (BBB) to deliver drugs for TBI treatment. This project aims to develop targted intranasally delivered, magnetically propulsed, and targted nanoparticles for traumatic brain injury (TBI). In Phase I, we will demonstrate the design, fabrication, and in vitro characterization of proposed drug laden magnetic nanoparticles as well as co ...

    STTR Phase I 2018 Department of DefenseDefense Health Agency
  3. Hybrid DNN-based Transfer Learning and CNN-based Supervised Learning for Object Recognition in Multi-modal Infrared Imagery

    SBC: TOYON RESEARCH CORPORATION            Topic: 1

    On this effort Toyon Research Corp. and The Pennsylvania State University are developing deep learning-based algorithms for object recognition and new class discovery in look-down infrared (IR) imagery. Our approach involves the development of a hybrid classifier that exploits both transfer learning and semi-supervised paradigms in order to maintain good generalization accuracy, especially when li ...

    STTR Phase I 2018 Department of DefenseNational Geospatial-Intelligence Agency
  4. Low-Cost Diagnostic Platform for Rapid Biochemical Detection

    SBC: Triton Systems, Inc.            Topic: DHA17B004

    Triton Systems will develop a novel approach to field-based disease and biochemical diagnostics through innovative use of extremely low cost bioanalytical devices.The proposed platform will provide a low cost, portable, and reliable diagnostic test for on-site use in austere and resource-limited environments.The devices will be highly durable, rugged, and easy to use without user-induced variation ...

    STTR Phase I 2018 Department of DefenseDefense Health Agency
  5. Oxygen Production and Delivery on Demand

    SBC: GLOBAL RESEARCH & DEVELOPMENT, INC.            Topic: DHA17B005

    This proposal is in response to the Defense Health Agency 2017 Phase I SBIR topic 17B-005.The approach is the use of a membrane oxygen pump using newly developed nano-thickness membranes with all the layers less than 1 micron total.Nanometer thickness membranes enable more oxygen output per surface area at temperatures of 300-600 C than current state-of-the -art 600-800 C membranes that are 50-300 ...

    STTR Phase I 2018 Department of DefenseDefense Health Agency
  6. AeroQUEST: Aeromedical Quantified Understanding via Experimental Standards Toolkit

    SBC: Aptima, Inc.            Topic: DHA17C001

    Adverse physiological events (PEs) have plagued warfighters piloting military aircraft, in particular PEs involving hypoxia and cockpit cabin decompression. Though there has been a large variety of research performed in trying to understand the problems and why theyre caused, there are inefficiencies due to the lack of standardized cross-laboratory protocols, procedures, and metrics. To address th ...

    STTR Phase I 2018 Department of DefenseDefense Health Agency
  7. Novel Circulating RNA-based Markers as Diagnostic Biomarkers of Infectious Diseases

    SBC: CFD Research Corporation            Topic: CBD18A001

    In resource limited settings, rapid and accurate diagnosis of infections is critical for managing potential exposures to highly virulent pathogens,whether occurring from an act of bioterrorism or a natural event. This is especially important for hard to detect intracellular bacterial andalphavirus infections, that overlap symptomatically and often treated empirically due to a lack of reliable and ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  8. Marburg Virus Prophylactic Medical Countermeasure

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: CBD18A002

    There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditionalvaccines have proven to be a huge contribution to public health, they do have some limitations especially in the cont ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  9. Virus-Like Particle Based pan-Marburgvirus Vaccine

    SBC: Luna Innovations Incorporated            Topic: CBD18A002

    Marburg virus (MARV) is a filamentous enveloped non-segmented negative sense RNA virus. This viruse is considered to be extremelydangerous with case fatality rates as high as 88-90%. Extensive efforts have gone towards effective vaccines for MARV prevention, however,none have been successfully established as licensed vaccines. Glycoprotein (GP) is the only surface protein of MARV. There are substa ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  10. Probabilistic Pharmacokinetic Models for Diagnosis, Prognosis, and Personalized Treatment

    SBC: BARRON ASSOCIATES, INC.            Topic: DHA17B003

    Clinicians have recognized that the nature of diseases can be highly individual resulting in different patterns of onset and progression. In turn, the response of an individual to drugs is also unique and governed by a variety of factors. Pharmacokinetic models represent the movement of a drug through the body, and personalized pharmacokinetic models aim to capture the unique responses of specific ...

    STTR Phase I 2018 Department of DefenseDefense Health Agency
US Flag An Official Website of the United States Government